<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4225</id>
  <title>T3D4171</title>
  <common-name>Asymmetric dimethylarginine</common-name>
  <description>Asymmetric dimethylarginine is a uremic toxin.  Uremic toxins can be subdivided into three major groups based upon their chemical and physical characteristics: 1) small, water-soluble, non-protein-bound compounds, such as urea; 2) small, lipid-soluble and/or protein-bound compounds, such as the phenols and 3) larger so-called middle-molecules, such as beta2-microglobulin. Chronic exposure of uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease. Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. Asymmetric dimethylarginine is created in protein methylation, a common mechanism of post-translational protein modification. This reaction is catalyzed by an enzyme set called S-adenosylmethionine protein N-methyltransferases (protein methylases I and II). The methyl groups transferred to create ADMA are derived from the methyl group donor S-adenosylmethionine, an intermediate in the metabolism of homocysteine. (Homocysteine is an important blood chemical, because it is also a marker of cardiovascular disease). After synthesis, ADMA migrates into the extracellular space and thence into blood plasma. Asymmetric dimethylarginine is measured using high performance liquid chromatography.</description>
  <cas>30315-93-6</cas>
  <pubchem-id>123831</pubchem-id>
  <chemical-formula>C8H18N4O2</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point>195 - 197°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Endogenous, Ingestion, Dermal (contact)</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Uremic toxins such as asymmetric dimethylarginine are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (A7868). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO.  KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (A7869). </mechanism-of-toxicity>
  <metabolism>Uremic toxins tend to accumulate in the blood either through dietary excess or through poor filtration by the kidneys. Most uremic toxins are metabolic waste products and are normally excreted in the urine or feces.</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Naturally produced by the body (endogenous).</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Chronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease.</health-effects>
  <symptoms>As a uremic toxin, this compound can cause uremic syndrome.  Uremic syndrome may affect any part of the body and can cause nausea, vomiting, loss of appetite, and weight loss. It can also cause changes in mental status, such as confusion, reduced awareness, agitation, psychosis, seizures, and coma. Abnormal bleeding, such as bleeding spontaneously or profusely from a very minor injury can also occur. Heart problems, such as an irregular heartbeat, inflammation in the sac that surrounds the heart (pericarditis), and increased pressure on the heart can be seen in patients with uremic syndrome. Shortness of breath from fluid buildup in the space between the lungs and the chest wall (pleural effusion) can also be present.</symptoms>
  <treatment>Kidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored.</treatment>
  <created-at type="dateTime">2014-08-29T05:49:09Z</created-at>
  <updated-at type="dateTime">2026-05-14T17:13:01Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Asymmetric dimethylarginine</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C03626</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>17929</chebi-id>
  <biocyc-id>CPD-596</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB01686</drugbank-id>
  <pdb-id>DA2</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>N[C@@H](CCC\N=C(/N)N(C)C)C(O)=O</moldb-smiles>
  <moldb-formula>C8H18N4O2</moldb-formula>
  <moldb-inchi>InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1</moldb-inchi>
  <moldb-inchikey>YDGMGEXADBMOMJ-LURJTMIESA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">202.2541</moldb-average-mass>
  <moldb-mono-mass type="decimal">202.14297584</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-2.7</logp>
  <hmdb-id>HMDB01539</hmdb-id>
  <chembl-id>CHEMBL457530</chembl-id>
  <chemspider-id>110375</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003131</chemdb-id>
  <dsstox-id>DTXSID6036758</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00068530</susdat-id>
  <iupac>(2S)-2-amino-5-[(E)-[amino(dimethylamino)methylidene]amino]pentanoic acid</iupac>
  <moldb-polar-surface-area>104.94</moldb-polar-surface-area>
  <moldb-refractivity>53.699600000000004</moldb-refractivity>
  <moldb-polarizability>22.186030281533142</moldb-polarizability>
  <moldb-rotatable-bond-count>5</moldb-rotatable-bond-count>
  <moldb-acceptor-count>6</moldb-acceptor-count>
  <moldb-donor-count>3</moldb-donor-count>
  <moldb-pka-strongest-acidic>2.539262506302749</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>12.34050755300345</moldb-pka-strongest-basic>
  <moldb-physiological-charge>1</moldb-physiological-charge>
  <moldb-number-of-rings>0</moldb-number-of-rings>
  <moldb-alogps-logp>-3.13</moldb-alogps-logp>
  <moldb-alogps-logs>-1.48</moldb-alogps-logs>
  <moldb-alogps-solubility>6.77e+00 g/l</moldb-alogps-solubility>
</compound>
